



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학석사 학위논문

The effect of intravenous  
dexmedetomidine on hemodynamic  
response in patients undergoing  
skull-pin head-holder application  
during neurosurgery

– A meta-analysis of randomized controlled trials

신경외과 수술에서 두개골 핀 고정시  
혈역학적 변화에 대한  
덱스메데토미딘의 효과  
– 무작위 대조시험의 메타분석

2021 년 2 월

서울대학교 대학원  
의학과 마취통증의학전공  
전 수 영

신경외과 수술에서 두개골 핀 고정시  
혈역학적 변화에 대한  
텍스메데토미딘의 효과  
- 무작위 대조시험의 메타분석

지도교수 김 진 희

이 논문을 의학석사 학위논문으로 제출함

2020 년 10 월

서울대학교 대학원  
의학과 마취통증의학 전공  
전 수 영

전수영의 석사 학위논문을 인준함

2021 년 1 월

위 원 장 김 재 용 (인)

부 위 원 장 김 진 희 (인)

위 원 유 정 희 (인)

## **Abstract**

# **The effects of intravenous dexmedetomidine on hemodynamic response in patients undergoing skull- pin head-holder application during neurosurgery – A meta-analysis of randomized controlled trials**

**Sooyoung Jeon**

**Department of Anesthesiology and Pain Medicine**

**College of Medicine**

**The Graduate School**

**Seoul National University**

**Objectives.** Skull-pin head-holder application during neurosurgery is a highly noxious stimulus that may lead to abrupt hemodynamic change, which is an unfavorable response to maintain hemodynamics stability. The aim of this meta-analysis was to evaluate the effects of intravenous dexmedetomidine on

hemodynamic response (blood pressure and heart rate) resulting from the application of skull-pin head-holder in neurosurgery.

**Methods.** A systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines. The protocol was registered with the International Prospective Register of Systematic Reviews (CRD 420119127876). Electronic databases were searched, without discrimination of publication year, language, and region, to identify all randomized controlled trials investigating the effects of dexmedetomidine on hemodynamic response resulting from skull-pin head-holder application during general anesthesia for neurosurgery. The mean arterial pressure and heart rate were analyzed using random-effect model, and the mean difference (MD) was calculated.

**Results.** Seventeen trials were identified; a total of 878 patients were enrolled. The analysis indicated that dexmedetomidine infusion reduced the mean arterial pressure (MD -11.70, 95% confidence interval [CI] -16.33 to -7.07,  $p < 0.00001$ ) and heart rate (MD -14.48, 95% CI -23.10 to -5.86,  $p = 0.001$ ) during skull-pin head-holder application. Subgroup analysis showed that dexmedetomidine was superior to fentanyl for the attenuation of hemodynamic response. Dexmedetomidine infusion also reduced the incidence of hypertension, tachycardia and brain relaxation score.

**Conclusion.** The result of this analysis indicates that intraoperative dexmedetomidine administration could decrease the hemodynamic response

and provide hemodynamic stability during skull-pin head-holder application in neurosurgery.

.....

**Keywords:** Dexmedetomidine; Hemodynamic response; intracranial surgery; Neurosurgery; Skull-pin head-holder; Brain relaxation score

**Student Number: 2009-21813**

# Contents

<b>Abstract.....</b>	<b>i</b>
<b>Contents.....</b>	<b>iv</b>
<b>List of table and figures.....</b>	<b>vi</b>
<b>Introduction.....</b>	<b>1</b>
<b>Materials and methods .....</b>	<b>3</b>
<b>Search strategy.....</b>	<b>3</b>
<b>Study selection.....</b>	<b>3</b>
<b>Data extraction.....</b>	<b>4</b>
<b>Quality assessment.....</b>	<b>5</b>
<b>Data synthesis and statistical analysis.....</b>	<b>5</b>
<b>Results .....</b>	<b>6</b>
<b>Characteristics of included studies.....</b>	<b>6</b>
<b>Methodological assessment and Risk of bias.....</b>	<b>6</b>

Mean arterial pressure.....	7
Heart rate.....	7
Hypertension and hypotension.....	8
Tachycardia and bradycardia.....	9
Brain relaxation score.....	10
<b>Discussion .....</b>	<b>19</b>
<b>Conclusion .....</b>	<b>22</b>
<b>References .....</b>	<b>23</b>
<b>Appendices.....</b>	<b>31</b>
<b>Appendix 1.....</b>	<b>31</b>
<b>Appendix 2.....</b>	<b>34</b>
<b>Abstract in Korean .....</b>	<b>44</b>



## List of table and figures

<b>Table 1. Baseline characteristics and population of the included randomized trials.....</b>	<b>11</b>
<b>Figure 1. CONSORT diagram of included and excluded studies....</b>	<b>13</b>
<b>Figure 2. Risk of bias summary and graph.....</b>	<b>14</b>
<b>Figure 3. Forest plots for the hemodynamic variables during skull fixation: (A) mean arterial blood pressure(mmHg) and (B)heart rate (rates/min).....</b>	<b>15</b>
<b>Figure 4. Forest plots for the hemodynamic events during surgery: (A) hypertension and (B) hypotension.....</b>	<b>16</b>
<b>Figure 5. Forest plots for the hemodynamic events during surgery: (A) tachycardia and (B) bradycardia.....</b>	<b>17</b>
<b>Figure 6. Forest plot for the brain relaxation score.....</b>	<b>18</b>

# Introduction

The application of skull-pin head-holder is necessary to fixate the head of patients for optimal surgical approach during neurosurgery. During the application process, the pins are inserted into the periosteum, yielding highly nociceptive stimulus, despite the general anesthesia [1]. This painful stimulus usually promotes sympathetic activity, inducing acute tachycardia or systemic hypertension, which could increase cerebral blood flow in patients with impaired autoregulation [2]. Subsequently, it may increase intracranial pressure and decrease cerebral perfusion pressure [3]. Impairment of cerebral homeostasis results in cerebral edema or cerebral ischemia. Therefore, it is important to maintain stable hemodynamics during skull fixation in patients undergoing craniotomy.

For the attenuation of hemodynamic response to nociceptive stimulus during skull fixation, many studies have investigated various interventions including regional techniques and pharmacologic treatments. However, regional techniques, including local anesthetic infiltration at the pin insertion site and scalp block, have shown the possibility of failure due to inaccurate infiltration site or inadequate anesthetic doses [4]. Pharmacologic approaches, such as opioid [5], beta-blocker [6], ketamine [4], gabapentine [7], clonidine [8], and thiopental [1] have shown varying success rate.

Dexmedetomidine, an alpha-2 agonist, has sedative, analgesic, and

sympatholytic effects without respiratory depression [9]. Dexmedetomidine has been reported to reduce the hemodynamic response from intraoperative stress [10, 11], and opioid consumption [12], and may reduce analgesic requirement in the intensive care unit [9]. Therefore, the aim of this meta-analysis was to evaluate the effect of dexmedetomidine on hemodynamic response from skull fixation via skull-pin head- holder in patients undergoing craniotomy.

# **Materials and methods**

## **Search strategy**

This systematic review and meta-analysis was performed according to the Preferred Items for Systematic Reviews and Meta Analyses (PRISMA) statement [13]. A predefined protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO : CRD 42019127876). We searched a variety of databases, including MEDLINE, EMBASE, CENTRAL, CINAHL, Scopus and Web of Science, to identify randomized controlled trials (RCTs) investigating the effects of dexmedetomidine on hemodynamic response from skull-pin application. The last search was conducted on January 9, 2020. MeSH terms and keywords, such as “craniotomy”, “neurosurgery”, “intracranial surgery”, “brain tumor”, “dexmedetomidine”, and “precedex” were used; each finding was combined with the Boolean operator: “AND” or “OR”. A detailed search strategy for each database is shown in Appendix 1.

## **Study selection**

Relevant studies were selected by screening the titles and abstracts. Subsequently, the full-texts of relevant studies were evaluated for eligibility. Two investigators independently conducted the process, and the third investigator participated in the selection process in the vent of a disagreement. The inclusion criteria were (1) randomized controlled trials, (2) patients

undergoing craniotomy, (3) use of intravenous dexmedetomidine infusion, and (4) reported outcomes related with intraoperative hemodynamics. We excluded the studies that did not report hemodynamic outcomes.

### **Data extraction**

Two investigators independently investigated and extracted the data from the original full-text of articles. The following data such as the first author, publication year, study design, publication language, number of patients, age, study drugs, drug dose regimen, any intervention just before skull fixation, anesthetics and intraoperative analgesics were retrieved. We used GetData Graph Digitizer 2.26 (<http://www.getdata-graph-digitizer.com>) to extract the mean and standard deviation if the data were reported only in a graph format. The primary outcome was defined as the mean arterial pressure (MAP) measured during skull pin application. Secondary outcomes included the heart rate (HR) during skull pin application, the incidence of intraoperative hemodynamic events (hypertension, hypotension, tachycardia and bradycardia) and brain relaxation score after opening the dura. The missing standard deviation of the value was imputed based on the following steps [14]: (1) standard deviation of value measured at different time-point, (2) standard deviation of systolic blood pressure at the same time-point, (3) standard deviation of systolic blood pressure at different time-points, (4) average standard deviation of value from other trials using the same intervention.

## **Quality assessment**

Two investigators independently assessed the methodological quality using the Cochrane Risk of bias tool. Risk of bias (selection bias, performance bias, detection bias, attrition bias and reporting bias) was graded as low, unclear, or high. If there was disagreement between two investigators, decision was made by discussion or with the third investigator.

## **Data synthesis and statistical analysis**

The meta-analysis was performed using Revman 5.3 software (Cochrane Collaboration, Oxford, UK). Since the pre-defined outcomes were continuous variables, we calculated the mean difference (MD) with 95% confidence intervals. We planned to construct a forest plot using a random effect model. We also performed a subgroup analysis according to the control group: (1) dexmedetomidine vs. other analgesics and (2) dexmedetomidine vs. normal saline. Heterogeneity among the included studies was assessed using an  $I^2$  statistic. Heterogeneity was graded as low ( $0 < I^2 < 50\%$ ), moderate ( $50\% \leq I^2 < 75\%$ ) or high ( $I^2 \geq 75\%$ ).

# Results

## Characteristics of included studies

A total of 837 articles were acquired from literature search; of these, 357 articles were removed due to duplicated retrieval. Among the remaining articles, 455 articles were identified as irrelevant studies based on the titles ( $n = 417$ ) and abstracts ( $n = 38$ ). Subsequently, 8 articles were excluded because they did not report the outcomes related with the present study ( $n=4$ ), they were conference abstracts ( $n=2$ ), or they focused on the postoperative periods ( $n=2$ ) (Fig.1). Hence, 17 RCTs ( $n=878$ ) were included in the final analysis [3, 15-30]. The characteristics of all included RCTs are shown in Table 1. The effect of dexmedetomidine was compared with placebo in 8 studies [3, 17-19, 24, 25, 27, 30], fentanyl in 6 studies [15, 16, 22, 23, 26, 28], remifentanyl in 2 studies [20, 29], and propofol in one study [21].

## Methodological assessment and Risk of bias

The risk of bias is summarized graphically in Fig. 2. All patients of the included studies were randomly allocated to one of two groups; however, six studies failed to describe the method of randomization. Most studies did not report the method of concealing the allocation process (14/17). In more than half of the included studies, it was clear that participants were unaware of their group assignment; however, it was unclear whether the assessors were blinded to group assignment. In most studies, the risk of attrition bias, reporting bias,

and other biases was regarded as low. Details for each risk of bias were described in Appendix 2.

### **Mean Arterial pressure**

MAP was reported in 11 RCTs, including 576 patients (Fig. 3A) [15, 16, 19, 21-25, 28-30]. Blood pressure was measured continuously by arterial catheter in seven studies [15, 19, 21, 23-25, 30], whereas it was measured intermittently by non-invasive cuff in two studies [22, 28]. There were no descriptions how to measure blood pressure in another two studies.[16, 29] MAP during skull-pin application was lower in the dexmedetomidine group than in the control group (MD -11.70, 95% CI -16.33 to -7.07,  $p < 0.00001$ ) and a high level of heterogeneity was found ( $I^2 = 93\%$ ,  $p < 0.00001$ ). In the subgroup analysis, the dexmedetomidine group showed a lower MAP than placebo group (MD -13.06, 95% CI -20.85 to -5.26,  $p = 0.001$ ,  $I^2 = 83\%$ ) and the fentanyl group (MD -16.65, 95% CI -20.05 to -13.25,  $p < 0.00001$ ,  $I^2 = 65\%$ ). However, there were no significantly differences in MAP in the dexmedetomidine group compared to the remifentanyl group (MD 2.48, 95% CI -3.64 to 8.60,  $p = 0.43$ ) and the propofol group (MD 5.90, 95% CI -0.27 to 12.07,  $p = 0.06$ ).

### **Heart rate**

HR during skull-pin application was reported in 10 RCTs, including 526 patients (Fig. 3B) [15, 16, 19, 21, 23-25, 28-30]. HR during skull-pin application was also lower in the dexmedetomidine group than in the control group (MD -14.48, 95% CI -23.10 to -5.86,  $p = 0.001$ ). A high level of



heterogeneity among the studies was found ( $I^2= 96\%$ ,  $p < 0.00001$ ). In the subgroup analysis, the HR was lower in the dexmedetomidine group compared with both the placebo group (MD -20.54, 95% CI -29.95 to -11.14,  $p < 0.0001$ ,  $I^2 = 88\%$ ) and fentanyl group (MD -16.62, 95% CI -26.94 to -6.29,  $p = 0.002$ ,  $I^2 = 91\%$ ). However, the HR in the dexmedetomidine group was comparable to remifentanyl group (MD -0.22, 95% CI -4.11 to 3.67,  $p = 0.91$ ) and propofol group (MD 2.90 95% CI -5.19 to 10.99,  $p = 0.48$ ).

### **Hypertension and hypotension**

The incidence of intraoperative hypertension was reported in 11 RCTs, including 607 patients (Fig. 4A) [3, 15-18, 20, 21, 25, 26, 28, 30]. The incidence of hypertension was lower in the dexmedetomidine group than in the control group (Relative risk [RR] 0.47, 95% CI 0.28 to 0.78,  $p = 0.004$ ). A moderate level of heterogeneity was found ( $I^2= 58\%$ ,  $p = 0.009$ ). In the subgroup analysis, intraoperative hypertension was observed less frequently in the dexmedetomidine group compared with placebo group (RR 0.38, 95% CI 0.21 to 0.69,  $p = 0.002$ ,  $I^2 = 54\%$ ). However, hypertensive events in dexmedetomidine group were similar to those in fentanyl group (RR = 0.19, 95% CI 0.03 to 1.17,  $p = 0.07$ ,  $I^2 = 61\%$ ), remifentanyl group (RR 1.33, 95% CI 0.51 to 3.49,  $p = 0.56$ ), and propofol group (RR 0.78, 95% CI 0.32 to 1.88,  $p = 0.58$ ).

The incidence of intraoperative hypotension was reported in 12 RCTs, including 610 patients (Fig. 4B) [3, 16-18, 20-23, 26-28, 30]. There were no

significant differences in the incidence of hypotension between two groups in both overall analysis (RR 1.07, 95% CI 0.72 to 1.58,  $p = 0.74$ ,  $I^2 = 24\%$ ) and subgroup analysis (vs placebo: RR 0.82, 95% CI 0.47 to 1.40,  $p = 0.46$ ,  $I^2 = 36\%$ ; vs fentanyl: RR 1.51, 95% CI 0.80 to 2.84,  $p = 0.21$ ,  $I^2 = 0\%$ ; vs remifentanyl: RR 0.50, 95% CI 0.10 to 2.58,  $p = 0.41$ ; vs propofol: RR 2.67, 95% CI 0.76 to 9.31,  $p = 0.12$ ).

### **Tachycardia and Bradycardia**

The incidence of tachycardia during surgery was reported in 7 RCTs, including 369 patients (Fig. 5A) [3, 15, 16, 18, 25, 28, 30]. Tachycardia was significantly less frequent in the dexmedetomidine group than in the control group (RR 0.18, 95% CI 0.07 to 0.46,  $p = 0.0004$ ) with low level of heterogeneity ( $I^2 = 24\%$ ,  $p = 0.25$ ). Subgroup analyses showed that dexmedetomidine reduced intraoperative tachycardia compared to placebo (RR 0.22, 95% CI 0.06 to 0.76,  $p = 0.02$ ,  $I^2 = 48\%$ ) and fentanyl (RR 0.08, 95% CI 0.01 to 0.62,  $p = 0.01$ ,  $I^2 = 0\%$ ).

Intraoperative bradycardia was reported in 9 RCTs, including 450 patients (Fig. 5B) [3, 16, 18, 21-23, 27, 28, 30]. There were no significant differences in the incidence of bradycardia between two groups in both overall analysis (RR 1.49, 95% CI 0.72 to 3.11,  $p = 0.28$ ,  $I^2 = 0\%$ ) and subgroup analysis (vs placebo: RR 1.81, 95% CI 0.29 to 11.32,  $p = 0.53$ ,  $I^2 = 51\%$ ; vs fentanyl: RR 2.70, 95% CI 0.51 to 14.16,  $p = 0.24$ ,  $I^2 = 0\%$ ; vs propofol: RR 1.20, 95% CI 0.40 to 3.61,  $p = 0.75$ ).

## **Brain relaxation score**


The brain relaxation score was assessed by a neurosurgeon in 5 RCTs [19, 20-23]; however, one of them reported only mean rank and sum of rank of brain relaxation scores which were incalculable to estimate pooled effect size [22]. Therefore, 4 RCTs were used to estimate the pooled effect size (Fig. 6) [19-21, 23]. The brain relaxation score was assessed on 3-, 4- or 5-points scales in each trials. It was divided as dichotomized outcomes: “low” (score 1) or “high” (score > 1). Low score means excellent, good, or no swelling, whereas high score means worsen, poor or swelling. The results of the present study indicated that dexmedetomidine could significantly decrease the incidence of high brain relaxation score (RR 0.50, 95% CI 0.28 to 0.89,  $p = 0.02$ ,  $I^2 = 44\%$ )

Table 1. Baseline characteristics and population of the included randomized trials (n=17)

Author	Year	Design	Language	No. of patients (DEX/Control)	Study drug	Dose regimen (infusion)		Additional intervention just before skull fixation	Anesthetics	Intraoperative analgesics (bolus)
						DEX	Control			
Alagol	2006	RCT	Turkish	20/20	DEX/FTN	1 µg/kg/h followed by 0.5 µg/kg/h	1 µg/kg	-	Sevo (both group)	FTN (both group)
Batra	2017	RCT	English	25/25	DEX/FTN	0.4 µg/kg/h	4 µg/kg	-	Iso (both group)	FTN (both group)
Bekker	2008	RCT	English	28/28	DEX/placebo	1 µg/kg over 10 min followed by 0.5 µg/kg/h	-	-	Sevo + rFTN (both group)	FTN (both group)
Chakrabarti	2018	RCT	English	25/24	DEX/placebo	0.5 µg/kg/h	-	-	PPF+FTN (both group)	FTN (both group)
El Dawlatly	2006	RCT	English	14/14	DEX/placebo	0.25 µg/kg over 10 min	-	Group I/III : LA (1% lidocaine)	Sevo (both group)	-
Gunduz	2009	RCT	English	40/40	DEX/rFTN	0.5 µg/kg over 10 min followed by 0.6 µg/kg/h	0.25 µg/kg/min	-	DEX: Sevo + DEX rFTN: Sevo + rFTN	-
Gunes	2005	RCT	English	39/39	DEX/PPF	0.6-1.2 mg/kg/h	3-10 mg/kg/h	-	DEX: DEX + rFTN PPF: PPF + rFTN	-
Gupta	2017	RCT	English	25/25	DEX/FTN	1 µg/kg over 10 min followed by 0.04-0.05 µg/kg/min	3 µg/kg followed by 0.02-0.03 µg/kg/min	FTN 1 µg/kg i.v. with LA (2% lignocaine 3-5ml)	Iso (both group)	-
Ilhan	2010	RCT	English	15/15	DEX/FTN	1 µg/kg over 10 min followed by 0.4-0.5 µg/kg/min	4 µg/kg followed by 0.02-0.03 µg/kg/min	FTN 2 µg/kg i.v. with LA (2% lidocaine 3-5 ml)	Iso (both group)	FTN (both group)
Jadhav	2017	RCT	English	30/30	DEX/placebo	1 µg/kg over 10 min followed by 0.5 µg/kg/h	-	-	Iso (both group)	-
Kondavagilu	2017	RCT	English	60/30	DEX/placebo	1 µg/kg over 10 min	-	LA (0.25% bupivacaine 2ml)	Iso (both group)	FTN (both group)

0.5 µg/kg over 10 min										
Soliman	2011	RCT	English	20/20	DEX/placebo	1 µg/kg over 20 min followed by 0.4 µg/kg/h	-	-	Sevo (both group)	FTN (both group)
Srignesh	2019	RCT	English	12/12	DEX/FTN	0.5 µg/kg/h	1 µg/kg/h	Scalp block (0.25% bupivacaine + 1% lignocaine)	Iso (both group)	FTN (both group)
Tanskanen	2006	RCT	English	35/18	DEX/placebo	Plasma concentration of 0.2 or 0.4 ng/ml	-	FTN 2 or 4 µg/kg	Iso (both group)	FTN (both group)
Thongrong	2017	RCT	English	30/30	DEX/FTN	1 µg/kg over 10 min	1 µg/kg	-	Sevo (both group)	-
Turgut	2009	RCT	English	25/25	DEX/rFTN	1 µg/kg over 15 min followed by 0.2-1 µg/kg/h	1 µg/kg over 15 min followed by 0.05-1 µg/kg/min	-	DEX: PPF + DEX rFTN: PPF + rFTN	-
Uyar	2008	RCT	English	20/20	DEX/placebo	1 µg/kg over 10 min	-	FTN 1 µg/kg + lidocaine 1.5mg/kg i.v.	Iso (both group)	FTN (both group)

Age are expressed as the mean ± SD, RCT = randomized controlled trials, DEX = dexmedetomidine, FTN = fentanyl, rFTN = remifentanal, PPF = propofol, LA = local anesthetics, i.v.=intravenous administration, Sevo = sevoflurane, Iso = isoflurane



**Figure 1. CONSORT diagram of included and excluded studies.**






Figure 2. Risk of bias summary and graph.

(A)




(B)



**Figure 3. Forest plots for the hemodynamic variables during skull fixation: (A) mean arterial blood pressure (mmHg) and (B) heart rate (rates/min)**



(A)



(B)





Figure 4. Forest plots for the hemodynamic events during surgery:

(A) hypertension and (B) hypotension

(A)



(B)





Figure 5. Forest plots for the hemodynamic events during surgery: (A) tachycardia and (B) bradycardia



**Figure 6. Forest plot for the brain relaxation score.**

## Discussion

The main finding of this study was that the use of dexmedetomidine may significantly reduce MAP and HR during the application of skull-pin head-holder. It also reduced the incidence of hypertension, tachycardia, and brain relaxation score intraoperatively. We found that dexmedetomidine attenuated the hemodynamic response from highly nociceptive stimulus. This finding is in agreement with previous studies which proved the preventive effect of dexmedetomidine on the hemodynamic response from intraoperative stressors, such as intubation [31, 32], extubation [33], pneumoperitoneum [34], and surgical incision [35].

In the subgroup analysis, patients in the dexmedetomidine group had greater hemodynamic stability than those in the fentanyl group during the skull-pin head-holder application process. This result correlates favorably well with previous study and supports the idea that dexmedetomidine provide great attenuation of intraoperative stress compared to fentanyl [36].

In addition to the MAP during the skull-pin head-holder application, the total incidence of hypertension and/or tachycardia was also evaluated during the surgery. The incidence of hypertension and/or tachycardia was significantly lower in the dexmedetomidine group than in the control group, which support the results of previous study [37].

The incidence of intraoperative hypotension was comparable between the two groups. Subgroup analysis also showed that the incidence of hypotension in the dexmedetomidine group was not higher than that in the control group (other anesthetics or normal saline). It is still controversial whether dexmedetomidine administration is associated with hypotension or not. Several authors reported dexmedetomidine-induced hypotension [38, 39, 40], whereas others insisted no significant differences in the incidence of hypotension between the dexmedetomidine group and the control group [41, 42]. According to the previous multivariate analysis [40], low MAP, high Acute Physiology and Chronic Health Evaluation (APACHE II) score, and history of coronary artery disease were independent factors for dexmedetomidine-induced hypotension. Given that our finding was based on RCTs including relatively healthy patients (American Society of Anesthesiologists class I-II or I-III), insignificant difference in the incidence of intraoperative hypotension between the two groups may be well explainable.

Brain relaxation means the firmness of the brain tissue during craniotomy and the degree of brain relaxation is an important aspect of neurosurgical conditions [43]. Brain relaxation score was significantly lower in the dexmedetomidine group, which can be explained by the decrease in cerebral blood flow caused by dexmedetomidine administration. This result may be interpreted as that dexmedetomidine infusion has favorable effect on brain relaxation. This is in line with the result of previous findings [22, 44], which

were excluded from this meta-analysis due to article type; a case series [44] and incalculable data (mean rank and sum of rank) [22].

There are several limitations in this study. First, the doses of dexmedetomidine were varied among the studies, which may result in a high level of heterogeneity among studies. Second, several studies conducted additional interventions such as local infiltration at the pin sites or opioid administration just prior to the skull-pin head-holder application [19, 22, 23, 25-27, 30], which may underestimate the effects of dexmedetomidine on hemodynamic response. Third, the pooled effect sizes of MAP and HR were estimated from the absolute values of hemodynamic parameters instead of the deviation from baseline. Most RCTs included in the present study report the absolute value of MAP and HR without the difference between the baseline and the skull fixation.

## **Conclusion**

In conclusion, this meta-analysis supports the concept that intravenous dexmedetomidine attenuates hemodynamic response and provides hemodynamic stability during the skull-pin head-holder application in patients undergoing neurosurgery.

## References

1. Doblár DD, Lim YC, Bayjab N, Frenette L. A comparison of alfentanil, esmolol, lidocaine, and thiopental sodium on the hemodynamic response to insertion of headrest skull pins. *J Clin Anesth*, 8 (1996), 31-35.  
[https://doi.org/10.1016/0952-8180\(95\)00169-7](https://doi.org/10.1016/0952-8180(95)00169-7).
2. Engberg, M, Melsen NC, Herlevsen P, Haraldsted V, Cold GE. Changes of blood pressure and cerebral arterio-venous oxygen content differences (AVDO<sub>2</sub>) with and without bupivacaine scalp infiltration during craniotomy. *Acta Anaesthesiol Scand*, 34 (1990), 346-349.  
<https://doi.org/10.1111/j.1399-6576.1990.tb03100.x>.
3. Soliman RN, Hassan AR, Rashwan AM, Omar AM. Prospective, randomized study to assess the role of dexmedetomidine in patients with supratentorial tumors undergoing craniotomy under general anaesthesia. *Middle East J Anaesthesio*, 21 (2011), 325-334.
4. Agarwa A, shina PK, Pandey CM, Gaur A, Pandey CK, Kaushok S. Effect of a subanesthetic dose of intravenous ketamine and/or local anesthetic infiltration on hemodynamic responses to skull-pin placement: A prospective, placebo-controlled, randomized, double-blind study. *J Neurosurg Anesthesiol*, 13 (2001), 189-194.  
<https://doi.org/10.1097/00008506-200107000-00002>.
5. Gunduz M, Gunes Y, Ozcengiz D, Ozalevli M. Anesthetic techniques for neurosurgery: Comparison of desflurane- remifentanil and desflurane-



- fentanyl in patients undergoing surgery for intracranial procedures.  
*Neurosurg Q*, 14 (2004), 204-208.
6. Kawaguchi M, Kawaraguchi Y, Yamamoto Y, Hayashi H, Abe R, Inoue S, Nakase H, Furuya H. Effects of landiolol on systemic and cerebral hemodynamics and recovery from anesthesia in patients undergoing craniotomy. *J Anesth*, 24 (2010), 503-510. <https://doi.org/10.1007/s00540-010-0931-4>.
  7. Misra S, Koshy T, Unnikrishnan KP, Suneel PR, Chatterjee N. Gabapentin Premedication Decreases the Hemodynamic Response to Skull Pin Insertion in Patients Undergoing Craniotomy. *J Neurosurg Anesthesiol*, 23 (2011), 110-117. <https://doi.org/10.1097/ANA.0b013e3181da3c3b>.
  8. Nagappa S, Kalappa S, Sridhara RB. Evaluation of the Hemodynamic Response of Intravenous Clonidine versus Ropivacaine Scalp Block to Insertion of Scalp Pins in Neurosurgical Patients. *Anesth Essays Res*, 12 (2018), 213-217. <https://doi.org/10.4103/0259-1162.194572>.
  9. Yu SB. Dexmedetomidine sedation in ICU. *Korean J Anesthesiol*, 62 (2012), 405-411. <https://doi.org/10.4097/kjae.2012.62.5.405>.
  10. El-Shmaa NS, El-Baradei GF. The efficacy of labetalol vs dexmedetomidine for attenuation of hemodynamic stress response to laryngoscopy and endotracheal intubation. *J Clin Anesth*, 31 (2016), 267-273. <https://doi.org/10.1016/j.jclinane.2016.01.037>.
  11. Srivastava VK, Nagle V, Agrawal S, Kumar D, Verma A, Kedia S. Comparative evaluation of dexmedetomidine and esmolol on hemodynamic

- responses during laparoscopic cholecystectomy. *J Clin Diagn Res*, 9 (2015), UC01-5. [https://doi.org/ 10.7860/JCDR/2015/11607.5674](https://doi.org/10.7860/JCDR/2015/11607.5674).
12. Rajan S, Hutcherson MT, Sessler DI, Kurz A, Yang D, Ghobrial M, Kiu J, Avitsian R. The Effects of Dexmedetomidine and Remifentanyl on Hemodynamic Stability and Analgesic Requirement After Craniotomy: A Randomized Controlled Trial. *J Neurosurg Anesthesiol*, 28 (2016), 282-290. <https://doi.org/10.1097/ANA.0000000000000221>.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*, 21 (2009), e1000097. <https://doi.org/10.1371/journal.pmed.1000097>.
14. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. *Cochrane Database Syst Rev*, 2010 (20), CD007893. <https://doi.org/10.1002/14651858.CD007893.pu b2>.
15. Alagol A, Kaya G, Colak A, Karacayir Y, Pamukcu Z, Turan F. Effects of dexmedetomidine infusion on hemodynamic responses in craniotomies. *Turk J Anaesthesiol Reanim*, 34 (2006), 236-240.
16. Batra A, Verma R, Bhatia VK, Chandra G, Bhushan S. Dexmedetomidine as an anesthetic adjuvant in intracranial surgery. *Anesth Essays Res*, 11 (2017), 309-313. [https://doi.org/ 10.4103/0259-1162.194555](https://doi.org/10.4103/0259-1162.194555).
17. Bekker A, Sturaitis M, Bloom M, Moric M, Golfinos J, Parker E, Babu R, Pitti A. The effect of dexmedetomidine on perioperative hemodynamics in patients undergoing craniotomy. *Anesth Analg*, 107 (2008), 1340-1347.

<https://doi.org/10.1213/ane.0b013e3181804298>.

18. Chakrabarti D, Kamath S, Reddy KRM, Srinivas DB, Manohar N, Masapu D. Effect of adjunctive dexmedetomidine on anesthesia and analgesia requirement and recovery characteristics during bispectral index-guided anesthesia for cerebello-pontine angle surgeries: a randomized clinical trial. *J Anaesthesiol Clin Pharmacol*, 34 (2018), 496-502.  
[https://doi.org/10.4103/joacp.JOACP\\_55\\_18](https://doi.org/10.4103/joacp.JOACP_55_18).
19. El Dawlatly AA, Abdullah K, Al Watidy S, Jamjoom Z, Murshid WR, Delvi B. Effect of small dose intravenous dexmedetomidine and/or local anaesthetic infiltration on haemodynamic responses to skull pin placement. *Pan Arab J Neurosurg*, 10 (2006), 29-33
20. Gunduz M, Gunes Y, Ozbek H, Yilmaz D, Isik G. Comparison of dexmedetomidine or remifentanil infusion combined with sevoflurane anesthesia in craniotomy: hemodynamic variables and recovery. *Neurosurg Q*, 19 (2009), 116-119. <https://doi.org/10.1097/WNQ.0b013e3181a45b0d>.
21. Gunes Y, Gunduz M, Ozcengiz D, Ozbek H, Isik G. Dexmedetomidine-remifentanil or propofol-remifentanil anesthesia in patients undergoing intracranial surgery. *Neurosurg Q*, 15 (2005), 112-126.  
<https://doi.org/10.1097/01.wnq.0000163345.17549.07>
22. Gupta A, Dwivedi Y, Saxena S, Srivastava Uma, Mangla S. A randomized control study of dexmedetomidine versus fentanyl as an anesthetic adjuvant in supratentorial craniotomies. *Anaesth Pain & Intensive Care*, 21 (2017), 306-311

23. Ilhan O, Koruk S, Serin G, Erkutlu I, Oner U. Dexmedetomidine in the supratentorial craniotomy. *Eurasian J Med*, 42 (2010), 61-65.  
<https://doi.org/10.5152/eajm.2010.19>.
24. Jadhav N, Wasekar N, Wagaskar V, Kondwilkar B, Patil R. Use of dexmedetomidine in patients undergoing craniotomies. *J Clin Diagn Res*, 11 (2017), UC01-UC08. <https://doi.org/10.7860/JCDR/2017/24002.9235>.
25. Kondavagilu SR, Pujari VS, Chadalawada MV, BEvinguddaiah Y. Low Dose Dexmedetomidine Attenuates Hemodynamic Response to Skull Pin Holder Application. *Anesth Essays Res*, 11 (2017), 57-61.  
<https://doi.org/10.4103/0259-1162.200229>.
26. Sriganesh K, Syeda S, Shanthanna H, Venkataramaiah S, Palaniswamy SR. Comparison of intraoperative fentanyl with dexmedetomidine for perioperative analgesia and opioid consumption during craniotomies: a randomised controlled pilot study with non-inferiority design. *Int J Clin Pract*, 73 (2019), e13338. <https://doi.org/10.1111/ijcp.13338>.
27. Tanskanen PE, Kytta JV, Randell TT, Aantaa RE. Dexmedetomidine as an anaesthetic adjuvant in patients undergoing intracranial tumour surgery: a double-blind, randomized and placebo-controlled study. *Br J Anaesth*, 97 (2006), 658-665. <https://doi.org/10.1093/bja/ael220>.
28. Thongrong C, Sirikannarat P, Kasemsiri P, Duangthongphon P. Comparison of dexmedetomidine and fentanyl to prevent haemodynamic response to skull pin application in neurosurgery: double blind randomized controlled trial. *Anaesthesiol Intensive Ther*, 49 (2017), 268-273.

<https://doi.org/10.5603/AIT.a2017.0051>.

29. Turgut N, Turkmen A, Ali A, Altan A. Remifentanil-propofol vs dexmedetomidine-propofol—anesthesia for supratentorial craniotomy. *Middle East J Anaesthesiol*, 20 (2009), 63-70.
30. Uyar AS, Yagmurdu H, Fidan Y, Topkaya C, Basar H. Dexmedetomidine attenuates the hemodynamic and neuroendocrinal responses to skull-pin head-holder application during craniotomy. *J Neurosurg Anesthesiol*, 20 (2008), 174-179. [https://doi.org/10.1097/ ANA.0b013e318177e5eb](https://doi.org/10.1097/ANA.0b013e318177e5eb).
31. Li Z, Su L, Zheng J, Wang Q. Comparison of Intravenous Dexmedetomidine versus Esmolol for Attenuation of Hemodynamic Response to Tracheal Intubation after Rapid Sequence Induction: A Systematic Review and Meta-Analysis. *Biomed Res Int*, 2019 (2019), 6791971. <https://doi.org/10.1155/2019/6791971>.
32. Yildiz M, Tavlan A, Tuncer S, Reisil R, Yosunkaya A, Otelcioglu S. Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation : perioperative haemodynamics and anaesthetic requirements. *Drugs R D*, 7 (2006), 43-52. <https://doi.org/10.2165/00126839-200607010-00004>.
33. Aksu R, Akin A, Bicer C, Esmoğlu A, Tosun Z, Boyacı A. Comparison of the effects of dexmedetomidine versus fentanyl on airway reflexes and hemodynamic responses to tracheal extubation during rhinoplasty: A double-blind, randomized, controlled study. *Curr Ther Res Clin Exp*, 70 (2009), 209-220. <https://doi.org/10.1016/j.curtheres.2009.06.003>.

34. Bhutia MP, Rai A. Attenuation of Haemodynamic Parameters in Response to Pneumoperitoneum during Laparoscopic Cholecystectomy: A Randomized Controlled Trial Comparing Infusions of Propofol and Dexmedetomidine. *J Clin Diagn Res*, 11 (2017), UC01-UC04. <https://doi.org/10.7860/JCDR/2017/26239.9810>.
35. Pestieau SR, Quezado ZM, Johnson YJ, Anderson JL. High-dose dexmedetomidine increases the opioid-free interval and decreases opioid requirement after tonsillectomy in children. *Can J Anaesth*, 58 (2011), 540-550. <https://doi.org/10.1007/s12630-011-9493-7>.
36. Vaswani JP, Debata D, Vyas V, Pattil S. Comparative Study of the Effect of Dexmedetomidine Vs. Fentanyl on Haemodynamic Response in Patients Undergoing Elective Laparoscopic Surgery. *J Clin Diagn Res*, 11 (2017), UC04-UC08. <https://doi.org/10.7860/JCDR/2017/27020.10578>.
37. McCutcheon CA, Orme RM, Scott DA, Davies MJ, McGlade DP. A comparison of dexmedetomidine versus conventional therapy for sedation and hemodynamic control during carotid endarterectomy performed under regional anesthesia. *Anesth Analg*, 102 (2006), 668-675. <https://doi.org/10.1213/01.ane.0000197777.62397.d5>.
38. Aryan HE, Box KW, Ibrahim D, Desiraju U, Ames CP. Safety and efficacy of dexmedetomidine in neurosurgical patients. *Brain Inj*, 20 (2006), 791-798. <https://doi.org/10.1080/02699050600789447>.
39. Wang D, Cao Y, Lyu Y, Li Y, Han T. Corrective effect of norepinephrine on hypotension induced by dexmedetomidine in critically ill patients. *Int J*

Clin Pharmacol Ther, 54 (2016), 987-991.

<https://doi.org/10.5414/CP202616>.

40. Gerlach AT, Blais DM, Jones GM, Burcham PK, Stawicki SP, Cook CH, Murphy CV. Predictors of dexmedetomidine-induced hypotension in critically ill patients. *Int J Crit Illn Inj Sci*, 6 (2016), 109-114.  
<https://doi.org/10.4103/2229-5151.190656>.
41. Su S, Ren C, Zhang H, Liu Z, Zhang Z. The opioid-sparing effect of perioperative dexmedetomidine plus sufentanil infusion during neurosurgery: a retrospective study. *Front Pharmacol*, 26 (2016), 407.  
<https://doi.org/10.3389/fphar.2016.00407>.
42. Le Guen M, Liu N, Tounou F, Augé M, Tuil O, Chazot T, Dardelle D, Laloë PA, Bonnet F, Sessler DI, Fischler M. Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-loop anesthesia: a double-blind, placebo-controlled trial. *Anesth Analg*, 118 (2014), 946-955.  
<https://doi.org/10.1213/ANE.000000000000185>.
43. Li J, Gelb AW, Flexman AM, Ji F, Meng L. Definition, evaluation, and management of brain relaxation during craniotomy. *Br J Anaesth*, 116 (2016), 759-769. <https://doi.org/10.1093/bja/aew096>.
44. Ard JL Jr, Bekker AY, Doyle WK (2005) Dexmedetomidine in awake craniotomy: a technical note. *Surg Neurol* 63:114-116; discussion 116-117.  
<https://doi.org/10.1016/j.surneu.2004.02.029>.

## Appendices

### Appendix 1. Search strategy for each database.

Database	Order	Keywords	Results
MEDLINE	#1	Neurosurgery[MH] OR “neurosurgical procedures”[MH] OR neurosurgery[TIAB] OR craniotomy[MH] OR “brain tumor”[TIAB] OR “brain surgery”[TIAB] OR craniotomy[TIAB] OR “neurosurgical patient*”[TIAB] OR “intracranial surgery”[TIAB]	233981
	#2	dexmedetomidine[MH] OR dexmedetomidine[TIAB] precedex[TIAB]	5655
	#3	#1 AND #2	292
	#4	#3 AND HSS(S)	143
EMBASE	#1	neurosurgery/exp OR neurosurgery:ab,ti OR craniotomy/exp OR craniotomy:ab,ti OR ‘brain tumor’:ab,ti OR ‘brain surgery’:ab,ti OR ‘neurosurgical patient*’:ab,ti OR ‘intracranial surgery’:ab,ti	316277
	#2	dexmedetomidine/exp OR dexmedetomidine:ab,ti OR Precedex:ab,ti	10767
	#3	#1 AND #2	563
	#4	'crossover procedure'/exp OR 'crossover procedure' OR 'double blind procedure'/exp OR 'double blind procedure' OR 'randomized controlled trial'/exp OR 'randomized controlled trial' OR 'single blind procedure'/exp OR 'single blind procedure' OR random* OR factorial* OR crossover* OR 'cross over' OR 'cross-over' OR placebo* OR (doubl* AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer*	2517584



	#5	#3 AND #4	156
CENTRAL	#1	[mh neurosurgery] OR [mh “neurosurgical procedures”] OR [mh craniotomy] OR craniotomy:ti,ab,kw OR “neurosurgical patient*”:ti,ab,kw OR neurosurgery:ti,ab,kw OR “brain tumor”:ti,ab,kw OR “brain surgery”:ti,ab,kw OR “intracranial surgery”:ti,ab,kw	9165
	#2	[mh dexmedetomidine] OR dexmedetomidine:ti,ab,kw OR precedex:ti,ab,kw	4367
	#3	#1 AND #2	165
	#4	#3 AND Trials	164
CINHAL	S1	MH(craniotomy+) OR MH(neurosurgery+) OR (TI(neurosurgery) OR AB(neurosurgery)) OR (TI(craniotomy) OR AB(craniotomy)) OR (TI(neurosurgical patient*) OR AB(neurosurgical patient*)) OR (TI(brain tumor) OR AB(brain tumor)) OR (TI(brain surgery) OR AB(brain surgery)) OR (TI(intracranial surgery) OR AB(intracranial surgery))	8542
	S2	(TI(dexmedetomidine) OR AB(dexmedetomidine)) OR (TI(precedex) OR AB(precedex))	477
	S3	S1 AND S2	22
SCOPUS	#1	INDEXTERMS(neurosurgical procedures) OR INDEXTERMS(neurosurgery) OR INDEXTERMS(craniotomy) OR TITLE-ABS(neurosurgery) OR TITLE-ABS(craniotomy) OR TITLE-ABS(neurosurgical patient*) OR TITLE-ABS(brain tumor) OR TITLE-ABS(brain surgery) OR TITLE-ABS(intracranial surgery)	242750
	#2	INDEXTERMS(dexmedetomidine) OR TITLE-ABS(dexmedetomidine) OR TITLE-	9134

		ABS(precedex)	
	#3	#1 AND #2	451
	#4	(INDEXTERMS(randomized controlled trial) OR INDEXTERMS(controlled clinical trial) OR TITLE-ABS(randomized) OR TITLE-ABS(placebo) OR INDEXTERMS(drug therapy) OR TITLE-ABS(randomly) OR TITLE-ABS(trial) OR TITLE-ABS(groups)) AND NOT (INDEXTERMS(animals) AND NOT INDEXTERMS(humans))	9056489
	#5	#3 AND #4	193
Web of Science	#1	TS=(neurosurgery) OR TS=(craniotomy) OR TS=(brain tumor) OR TS=(brain surgery) OR TS=(neurosurgical patient*) OR TS=(intracranial surgery)	184089
	#2	TS=(dexmedetomidine OR precedex)	6864
	#3	#1 AND #2	349
	#4	TS=(clinical trial* OR research design OR comparative stud* OR evaluation stud* OR controlled trial* OR follow-up stud* OR prospective stud* OR random* OR placebo* OR "single blind*" OR double blind*)	4318533
	#5	#3 AND #4	159

Appendix 2. Details for judgement for each risk of bias for randomized controlled studies.

Study	Bias	Author's judgement	Reason for judgement
Alagol 2006	Random generation (selection bias)	sequence Low	The study and control groups were randomly determined by the envelope withdrawal method (translated)
	Allocation concealment (selection bias)	Unclear	There is no description.
	Blinding (performance)	Unclear	There is no description.
	Blinding (detection bias)	Low	The anesthetist who recorded the data was not informed about the contents of infusion solutions and iv bolus injectors (translated)
	Incomplete outcome data (attrition bias)	Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)	Low	All pre-specified and expected outcomes are reported.
	Other bias	Low	No other bias was detected.
Batra 2017	Random generation (selection bias)	sequence Low	Balanced randomization was done using random computer-generated table.
	Allocation concealment (selection bias)	Unclear	There is no description.
	Blinding (performance)	Low	Both the teams were blinded to the drugs by supplying prefilled syringes with same volume of normal saline and dexmedetomidine in saline.

	Blinding (detection bias)	Unclear	There is no description
	Incomplete outcome data (attrition bias)	Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)	High	Some predefined outcomes were not reported
	Other bias	Low	No other bias was detected.
Bekker 2008	Random sequence generation (selection bias)	Unclear	Patients were randomized to one of two groups but the methods were not described.
	Allocation concealment (selection bias)	Unclear	There is no description
	Blinding (performance)	Low	The anesthetic was managed by experienced neuro-anesthesiologists blinded to DEX or placebo regimen
	Blinding (detection bias)	Low	The intraoperative hemodynamic data obtained by machine.
	Incomplete outcome data (attrition bias)	High	Seventy two patients were recruited and two patients were removed. But outcomes were reported for 56 patients.
	Selective reporting (reporting bias)	Low	All pre-specified and expected outcomes are reported.
	Other bias	Low	No other bias was detected.
Chakrabarti 2018	Random sequence generation (selection bias)	Low	Randomization to the study group was performed at 1:1 ratio by a computer-generated random number table
	Allocation concealment	Unclear	There is no description

		(selection bias)			
		Blinding (performance)	Low		The attending anesthesiologist was blinded by providing fentanyl or premixed fentanyl and dexmedetomidine as colorless solutions in an unlabelled 50 mL syringe for constant infusion at 0.125 mL/kg/hour
		Blinding (detection bias)	Unclear		There is no description
		Incomplete outcome data (attrition bias)	Low		Outcomes were reported for all patients.
		Selective reporting (reporting bias)	Low		All pre-specified and expected outcomes are reported.
		Other bias	Low		No other bias was detected.
El 2006	Dawlatly	Random sequence generation (selection bias)	Unclear		Patients were randomly allocated to groups but the methods were not described.
		Allocation concealment (selection bias)	Unclear		There is no description.
		Blinding (performance bias)	Low		Both the anesthetist who administered i.v. medications and the surgeon who performed local infiltration to the scalp were blinded to various treatment groups.
		Blinding (detection bias)	Unclear		There is no description.
		Incomplete outcome data (attrition bias)	Low		Outcomes were reported for all patients.
		Selective reporting	Low		Heart rate at pre-defined time point

	(reporting bias)			was not reported.
	Other bias		Low	No other bias was detected.
Gunduz 2009	Random sequence generation		Unclear	Patients were randomly allocated in 2 groups but the methods were not described.
	(selection bias)			
	Allocation concealment		Unclear	There is no description.
	(selection bias)			
	Blinding		Unclear	There is no description.
	(performance bias)			
	Blinding		Unclear	There is no description.
	(detection bias)			
	Incomplete outcome data		Low	Outcomes were reported for all patients.
	(attrition bias)			
	Selective reporting		Low	Heart rate at pre-defined time point was not reported.
	(reporting bias)			
	Other bias		Low	No other bias was detected.
Gunes 2005	Random sequence generation		Unclear	Patients were randomly allocated in 2 groups but the methods were not described.
	(selection bias)			
	Allocation concealment		Unclear	There is no description.
	(selection bias)			
	Blinding		Unclear	There is no description.
	(performance bias)			
	Blinding		Unclear	There is no description.
	(detection bias)			
	Incomplete outcome data		Low	Outcomes were reported for all patients.
	(attrition bias)			

	Selective reporting (reporting bias)	Low	Heart rate at pre-defined time point was not reported.
	Other bias	Low	No other bias was detected.
Gupta 2017	Random sequence generation (selection bias)	Low	Patients were randomized into two groups on the basis of computer generated random table.
	Allocation concealment (selection bias)	Unclear	There is no description.
	Blinding (performance bias)	Low	Our study was double blind in which the resident who was giving the drug was not aware about the drug and in postoperative care unit the sister on duty did the monitoring and recorded the results.
	Blinding (detection bias)	Low	Same as above
	Incomplete outcome data (attrition bias)	Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)	High	Heart rate at pre-defined time point was not reported.
	Other bias	Low	No other bias was detected.
Ilhan 2010	Random sequence generation (selection bias)	Unclear	The patients were randomized in two groups, but the method was not described.
	Allocation concealment (selection bias)	Unclear	There is no description.
	Blinding (performance bias)	Unclear	There is no description.

	Blinding (detection bias)	Unclear	There is no description.
	Incomplete outcome data (attrition bias)	Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)	Low	All pre-specified and expected outcomes are reported.
	Other bias	Low	No other bias was detected.
Jadhav 2017	Random sequence generation (selection bias)	Low	They were randomly divided into two groups by simple random sampling method
	Allocation concealment (selection bias)	Unclear	There is no description.
	Blinding (performance bias)	Unclear	There is no description.
	Blinding (detection bias)	Unclear	There is no description.
	Incomplete outcome data (attrition bias)	Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)	Low	All pre-specified and expected outcomes are reported.
	Other bias	High	Our study is limited by small sample size and lack of comparative data in humans.
Kondavagilu 2017	Random sequence generation (selection bias)	Low	Patients were randomly allocated to one of the three groups using computer-generated table of random numbers.
	Allocation concealment	Unclear	There is no description.



	(selection bias)			
	Blinding (performance bias)	Low		Dexmedetomidine of different doses or placebo was diluted by an independent investigator. The test drug infusion was initiated by the attending anesthesiologist who was blinded to the test drug
	Blinding (detection bias)	Unclear		There is no description.
	Incomplete outcome data (attrition bias)	Low		Outcomes were reported for all patients.
	Selective reporting (reporting bias)	Low		All pre-specified and expected outcomes are reported.
	Other bias	Low		No other bias was detected.
Soliman 2011	Random sequence generation (selection bias)	Unclear		The patients were randomized in two groups, but the method was not described.
	Allocation concealment (selection bias)	Unclear		There is no description.
	Blinding (performance bias)	Unclear		There is no description.
	Blinding (detection bias)	Unclear		There is no description.
	Incomplete outcome data (attrition bias)	Low		Outcomes were reported for all patients.
	Selective reporting (reporting bias)	Low		All pre-specified and expected outcomes are reported.
	Other bias	Low		No other bias was detected.

Sriganesh 2019	Random generation (selection bias)	sequence	Low	Randomisation was performed using a computer-generated random number table with 1:1 allocation ratio by an anaesthesiologist not directly involved in the trial or patient care
	Allocation concealment (selection bias)		Low	The group allocation list was discreetly shared with the anaesthesia technician (not involved in the intraoperative management)
	Blinding (performance bias)		Low	Both the study drugs were prepared in an identical 50 cc syringe as colourless solutions and provided to the operating room anaesthesiologist for administration to ensure blinding.
	Blinding (detection bias)		Low	Outcome assessor and the data analyst were blinded to the group allocation.
	Incomplete outcome data (attrition bias)		Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)		Low	All pre-specified and expected outcomes are reported.
	Other bias		Low	No other bias was detected.
Tanskanen 2006	Random generation (selection bias)	sequence	Low	Balanced randomization using permuted blocks was applied.
	Allocation concealment (selection bias)		Unclear	There is no description
	Blinding (performance bias)		Low	In order to keep the investigators blind to the study treatment, the Hospital Pharmacy diluted DEX or placebo with sodium chloride solution 0.9% into a ready-to-use form.

	Blinding (detection bias)		Unclear	There is no description
	Incomplete outcome data (attrition bias)		Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)		Low	All pre-specified and expected outcomes are reported.
	Other bias		Low	No other bias was detected.
Thongrong 2017	Random sequence generation (selection bias)		Low	The random numbers were generated by computer
	Allocation concealment (selection bias)		Low	And concealed in sealed envelope.
	Blinding (performance bias)		Low	These study drugs were prepared by an anaesthetist nurse who was not involved in the study.
	Blinding (detection bias)		Low	Blood pressure, mean arterial pressure, and heart rate were recorded by a blinded anaesthesiologist.
	Incomplete outcome data (attrition bias)		Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)		Low	All pre-specified and expected outcomes are reported.
	Other bias		Low	No other bias was detected.
Turgut 2009	Random sequence generation (selection bias)		Low	The allocation was done by a computer-generated codes based on a two-way randomization
	Allocation concealment (selection bias)		Low	Kept in sequentially numbered envelopes

	Blinding (performance bias)	Unclear	There is no description
	Blinding (detection bias)	Low	A blinded investigator assessed the outcomes
	Incomplete outcome data (attrition bias)	Low	Outcomes were reported for all patients.
	Selective reporting (reporting bias)	Low	All pre-specified and expected outcomes are reported.
	Other bias	Low	No other bias was detected.
Uyar 2008	Random sequence generation (selection bias)	Low	Patients were randomly allocated to one of 2 groups with the help of a computer-generated table of random numbers.
	Allocation concealment (selection bias)	Unclear	There is no description.
	Blinding (performance bias)	Low	DEX or placebo was diluted by one authors who was blinded to the recorded data
	Blinding (detection bias)	Unclear	There is no description.
	Incomplete outcome data (attrition bias)	Low	Outcomes were reported for all patients
	Selective reporting (reporting bias)	Low	All pre-specified and expected outcomes are reported.
	Other bias	Low	No other bias was detected.

## 국 문 초 록

**연구 배경.** 신경외과 수술에서 두개골 핀 고정은 갑작스러운 혈역학적 변화를 일으키는 매우 강력한 자극으로 알려져 있다. 이 메타분석의 목적은 신경외과 수술에서 두개골 핀 고정시 발생하는 혈역학적 변화(혈압 및 심박수)에 텍스메데토미딘 주입이 어떤 영향을 미치는지에 대한 효과를 평가하기 위한 것이다.

**연구 방법.** 전신마취 중 신경외과 수술에서 두개골 핀 고정시 혈역학적 변화에 미치는 텍스메데토미딘의 효과에 대한 무작위 대조시험을 대상으로 문헌검색을 하였다. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 지침에 따라 체계적인 검토 및 메타 분석을 수행하였고 이 프로토콜은 International Prospective Register of Systematic Reviews (CRD 420119127876)에 등록되었다. 변량효과모형 (random-effect models)을 사용하여 평균동맥압과 심박수를 분석하였고 평균차 (mean difference, MD)를 계산하였다.

**결과.** 878명의 환자가 포함된 17개의 연구를 분석하였다. 두개골 핀 고정시 텍스메데토미딘 주입은 평균 동맥압을 평균차  $-11.70$ , 95% 신뢰구간  $-16.33$  to  $-7.07$ ,  $p < 0.00001$ , 심박수를 평균차  $-14.48$ ,

95% CI -23.10 to -5.86,  $p = 0.001$ 만큼 감소시켰다. 하위집단(subgroup) 분석에서는 텍스메데토미딘이 펜타닐에 비해 혈액학적 반응을 완화시키는 것이 더 우수하였다. 또한 텍스메데토미딘은 고혈압, 빈맥, 뇌이완점수(brain relaxation score)를 감소시켰다.

**결론.** 신경외과 수술에서 두개골 핀 고정시 텍스메데토미딘 주입은 혈액학적 변화를 감소시켜 혈액학적 안정성을 제공할 수 있다.

.....  
**주요어:** 텍스메데토미딘; 혈액학적 반응; 두개내 수술; 신경외과 수술; 두개골 핀 고정; 뇌이완점수

**학 번:** 2009-21813